The largest database of trusted experimental protocols

36 protocols using staurosporine

1

Apoptosis Induction in Breast Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Abemaciclib and lapatinib (Haoyuan Chemexpress) were diluted as previously described6 (link). For in vitro use, palbociclib was diluted in DMSO. Cleaved PARP was measured after 48 hours of treatment with DMSO, lapatinib, or Abemaciclib. Lapatinib was used at 30 nM for BT474 and SKBR3; 500 nM for MDA-MB-453 and MDA-MB-361. Abemaciclib was used at 300 nM for BT474 and SKBR3; 25 nM for MDA-MB-453; 500 nM for MDA-MB-361. For staurosporine experiments, MDA-MB-453 cells were pretreated with DMSO or Abemaciclib (500 nM) for 0, 1, or 7 days prior to exposure to staurosporine (500nM, Enzo Life Sciences) for 4 hours. For hormonal therapy studies, cells were treated with combinations of DMSO, Abemaciclib (100 nM), and fulvestrant (100 nM, Sigma Aldrich). To determine JAK dependency, cells were treated with combinations of DMSO, Abemaciclib (500nM), and ruxolitinib (500nM, Selleckchem) for 7 days.
+ Open protocol
+ Expand
2

Apoptosis Induction in Breast Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Abemaciclib and lapatinib (Haoyuan Chemexpress) were diluted as previously described6 (link). For in vitro use, palbociclib was diluted in DMSO. Cleaved PARP was measured after 48 hours of treatment with DMSO, lapatinib, or Abemaciclib. Lapatinib was used at 30 nM for BT474 and SKBR3; 500 nM for MDA-MB-453 and MDA-MB-361. Abemaciclib was used at 300 nM for BT474 and SKBR3; 25 nM for MDA-MB-453; 500 nM for MDA-MB-361. For staurosporine experiments, MDA-MB-453 cells were pretreated with DMSO or Abemaciclib (500 nM) for 0, 1, or 7 days prior to exposure to staurosporine (500nM, Enzo Life Sciences) for 4 hours. For hormonal therapy studies, cells were treated with combinations of DMSO, Abemaciclib (100 nM), and fulvestrant (100 nM, Sigma Aldrich). To determine JAK dependency, cells were treated with combinations of DMSO, Abemaciclib (500nM), and ruxolitinib (500nM, Selleckchem) for 7 days.
+ Open protocol
+ Expand
3

Apoptotic Bodies Isolation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lewis lung carcinoma (LLC1) cells were obtained from the American Type Culture Collection (ATCC, Baltimore, U.S.A.). Cultures were maintained in RPMI-1640 supplemented with 10% FCS. All experiments were carried out within 6 months of resuscitation. LLC1 cells were incubated with etoposide (400 μM), curcumin (160 μM), tamoxifen (40 μM), staurosporine (1 μM), cisplatin (400 μM) or 5-fluorouracil (160 μM) (all from Enzo Life Sciences) for 24 hrs to induce apoptosis. Apoptotic bodies were purified as described by Fransen et al., 2009 (28 (link)); briefly, cells were centrifuged at 1500 g for 10 mins at 20°C. The supernatant was centrifuged at 15700 g for 50 mins at 20°C. Apoptotic bodies were resuspended in PBS.
4 x 106 LLC1 cells were incubated with 100 µl RIPA buffer containing a protease inhibitor cocktail (20 µl/ml; Calbiochem), phosphatase inhibitor (Thermo Scientific) and 1% Triton X-100 for 20 mins at 4°C. Supernatants, collected after centrifugation at 18000 g for 30 mins at 4°C, were employed as cell lysate.
+ Open protocol
+ Expand
4

Cell Cycle and Apoptosis Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
For cell cycle analysis, cells were serum-starved for 24 h and stimulated with HRG (20 ng/ml) for other 24 h. Cells were then harvested with 1 mM EDTA, washed with PBS, and fixed with ice-cold 100% ethanol. After washing again with PBS, cells were resuspended in Propidium Iodide (PI)/RNase Staining Solution (Cell Signaling Technology). Samples were analyzed on a BD FACSCalibur (BD Biosciences) and data were examined with FlowJo V10 software. Cyclin D1 antibody was detected by Western blot using an antibody from BD Biosciences.
For induction of apoptosis by anoikis, cell culture plates were coated with 6 mg/ml poly-HEMA (Sigma-Aldrich) in 95% ethanol and incubated at 37°C for several hours until they dry, and then washed with PBS. For single cell isolation, cells in suspension were passed through a 40 µm cell strainer (BD Biosciences) that retained the clumped cells, and then grown at low confluency (1 × 104 cells/ml) to avoid cell-cell contact. Apoptosis was also induced by staurosporine (1 µM, 3–6 h, Enzo Life Science, Farmingdale, NY, USA). Total and cleaved PARP were detected by Western blot using an antibody from Cell Signaling Technology.
+ Open protocol
+ Expand
5

Immune Cell Activation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fura-2/acetoxymethyl ester (AM) was purchased from Molecular Probes (Eugene, OR). Pam3Cys4 and staurosporine were purchased from Enzo Life Science (Farmingdale, NY). Phorbol-12-myristate-13-acetate (PMA), fMLP, LPS (Escherichia coli 0111:B4), and lipoteichoic acid were from Sigma-Aldrich (St Louis, MO). Digitonin was from Biosynth (Napcr-ville, IL). C5a and keratinocyte-derived cytokine (KC) were purchased from R&D (Minneapolis, MN) and Peprotech (Rocky Hill, NJ), respectively.
+ Open protocol
+ Expand
6

Erlotinib Cytotoxicity Assay in Fibroblasts

Check if the same lab product or an alternative is used in the 5 most similar protocols
To examine whether erlotinib treatment affected cell viability, we performed an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay using the Vybrant® MTT Cell Proliferation Kit (Invitrogen, Carlsbad, CA). Fibroblasts were plated in a 96-well plate according to published procedures (van Meerloo, Kaspers, & Cloos, 2011 (link)). Erlotinib was added to cell culture media to produce four final concentrations of 1μM, 2μM, 5μM and 10μM (Ali et al., 2008 (link); X. Chen et al., 2013 (link); Ling, Lin, & Pérez-Soler, 2008 (link); Orzáez, Guevara, Sancho, & Pérez-Payá, 2012 (link)). These concentrations were chosen to reflect the range of toxicity of erlotinib in vitro and clinically achievable doses (1–2 μM). The same amount of solvent (DMSO) was added to all samples, vehicle (DMSO; positive control for erlotinib), and staurosporine (positive control for cell death; Enzo Life Sciences, Farmingdale, NY) to control for any potential toxicity associated with the solvent. Each well was treated with one dose daily for three days at the same time each day. The MTT assay was performed according to a standard protocol and read at 570nm/1(s). The experiment was performed in triplicate. The no treatment condition was designated as the reference group.
+ Open protocol
+ Expand
7

Apoptosis in T cell subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood from healthy donors at different ages was obtained from the Asturias Transfusion Centre and the Internal Medicine Department of the Hospital Central de Asturias, Spain, after obtaining informed consent in accordance with the Declaration of Helsinki and following approval by the hospital's Ethics Committee. Healthy status was defined as the absence of autoimmune diseases, cancer, infectious diseases, dementia, and cardiovascular diseases that could interfere with the study. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation. CD28null and CD28+ T cells were purified using a CD4 Multisort kit and CD28 MicroBead kit (Miltenyi Biotec, Bergisch Gladbach, Germany) or sorted with a BD FACSARIA II cytometer (BD Bioscience, San José, CA, USA) after staining with CD4‐APC and CD28‐FITC monoclonal antibodies (Abs; BioLegend, San Diego, CA, USA). Purity was > 95% for all samples. Staurosporine (50 nm; Enzo Life Science, Lausen, Switzerland) was added to isolated PBMCs for 18 h to induce apoptosis.
+ Open protocol
+ Expand
8

Synthesis and Characterization of (+)-Betulin

Check if the same lab product or an alternative is used in the 5 most similar protocols
(+)-Betulin (> 95% purity) was synthetized by reduction of C-28 carboxylic acid group from (+)-betulinic acid, isolated from Cyrilla racemiflora (12 (link)–13 (link)), and purchased from Sigma-Aldrich (> 98% purity; St Louis, MO, USA), together with staurosporine, cycloheximide, paclitaxel, and sulforhodamine B. Rocaglamide was purchased from Enzo Life Sciences, Inc (Farmingdale, NY, USA). Tumor necrosis factor-α (TNFα) and NE-PER® nuclear and cytoplasmic extraction reagents kits were obtained from Thermo Scientific (Rockford, IL, USA). The mitochondrial transmembrane potential (MTP) assay kit was purchased from Cayman Chemical Company (Ann Arbor, MI, USA). An ELISA™ NF-κB p65 kit was obtained from Invitrogen (Carlsbad, CA, USA). Primary antibodies (anti-NF-ĸBp65, anti-NF-ĸBp50, anti-IKKα, anti-IKKβ, anti-caspase-3, anti-caspase-7, anti-Bcl-2, anti-ICAM-1 and anti-β-actin) were purchased from Cell Signaling Technologies (Beverly, MA, USA). Anti-rabbit or anti-mouse horseradish peroxidase (HRP)-conjugated antibody was purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA).
+ Open protocol
+ Expand
9

Evaluation of Apoptosis Inducers

Check if the same lab product or an alternative is used in the 5 most similar protocols
Sodium azide, anisomycin and doxycycline (dox) were purchased from Sigma (St Louis, MO, USA). zVAD-fmk, SP600125 and staurosporine were purchased from Enzo Life Sciences (Farmingdale, NY, USA). Etoposide was purchased from EBEWE Pharma (Kundl, Austria) and cisplatin was purchased from TEVA ABIC (Netanya, Israel).
+ Open protocol
+ Expand
10

Virus Infection and Apoptosis Induction

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were incubated for 1 h with VSV or HSV-1 in serum-free medium or pseudotyped virus in PBS 0.1% BSA, and then the inoculum was removed and incubation continued in complete media. Cells were incubated for 4 h with trans-packaged HCV, and then the inoculum was removed and incubation continued in complete media containing 60µM IRE1 Inhibitor II (Calbiochem). zVAD (Invivogen) was added at 20–100 µM after removal of the viral inoculum. Poly I:C (1 µg/mL) was delivered complexed to Lipofectamine 2000 (Invitrogen). Cells were treated with 0.1–1µM staurosporine (Enzo Life Sciences), 1µM gliotoxin (Sigma), 10µM ABT-737 (Santa Cruz Biotechnology), 50ng/ml TNF + 0.1µg/ml cycloheximide (Abcam), 2 µg/ml anti-mouse CD95 (BD Pharmingen) Fas activating antibody + 0.1µg/ml cycloheximide, 10–100µg/ml tunicamycin (Sigma), 1µM thapsigargin (Calbiochem) or 100µg/ml cycloheximide (high dose CHX). Cells were treated with IRE1 inhibitor 4µ8C (8-Formyl-7-hydroxy-4-methylcoumarin, Calbiochem) or the structurally similar compound AMC (7-Amino-4-methylcoumarin, Sigma) at 25µM for 3 days prior to infection or apoptosis induction, or 40µM IRE1 Inhibitor II (Calbiochem) for 24 h prior to apoptosis induction.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!